EIA
ACAD icon

Emerald Investment Advisers’s Acadia Pharmaceuticals ACAD Stock Holding History

Emerald Investment Advisers’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.33M Buy
131,752
+21,713
+20% +$478K 0.22% 147
2026
Q1 		$2.45M Buy
+110,039
New +$2.63M 0.22% 145

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Emerald Investment Advisers's ACAD Position: Q2 2026 in Review

Emerald Investment Advisers increased its Acadia Pharmaceuticals (ACAD) stake by 20% in Q2 2026, buying an estimated $478K and bringing the position to 131,752 shares worth $3.33M. The position accounts for 0.22% of the portfolio, ranked #147.

Emerald Investment Advisers first reported a position in ACAD in Q1 2026 and has held it in 2 quarters since. 350 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

  • Emerald Investment Advisers held 131,752 shares of Acadia Pharmaceuticals worth $3.33M as of Q2 2026.
  • Emerald Investment Advisers bought 21,713 Acadia Pharmaceuticals shares in Q2 2026, an estimated $478K.
  • Acadia Pharmaceuticals made up 0.22% of Emerald Investment Advisers's portfolio in Q2 2026, its #147 holding.
  • Emerald Investment Advisers first reported a position in Acadia Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 350 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Emerald Investment Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.